Department of Biochemistry and Medicine, La Salle University School of Medicine, Mexico City, Mexico.
Department of Pathology, Angeles del Pedregal Hospital, Mexico City, Mexico.
Am J Case Rep. 2020 Nov 12;21:e928046. doi: 10.12659/AJCR.928046.
BACKGROUND Riedel's thyroiditis is a rare form of immunoglobulin G (IgG) 4-related invasive fibrosis of the thyroid gland; given its scarce incidence, standardized therapeutic guidelines are unavailable. Although complications are unusual, obstructive symptoms produced by the stony-hard goiter may put patients' lives at risk. The diagnosis must be biopsy-proven, and treatment consists of thyroid hormone replacement and anti-inflammatory drugs, although sometimes thyroidectomy may be required. CASE REPORT A 69-year-old woman presented with a 7-month history of progressive hypothyroidism and obstructive dysphagia. On physical examination, she had a large, stony-hard goiter. A Doppler ultrasound study revealed a massive, avascular enlargement of the thyroid gland. A computed tomography scan failed to demonstrate any extrathyroidal extension of the abnormal tissue. A Tru-Cut biopsy of the thyroid was performed. Extensive replacement of thyroid follicles by prominent bands of fibrous tissue was observed, with follicular obliteration and mild focal occlusive phlebitis. A lymphoplasmacytic infiltrate was clearly identified; no oxyphilic nor giant cells were found. On immunohistochemistry, the immunoglobulin G (IgG) 4/IgG ratio in the plasma cell infiltrate was 40%; increased serum IgG4 levels were also found, supporting the diagnosis of Riedel's thyroiditis. The patient was successfully treated with levothyroxine replacement and tamoxifen with prompt resolution of obstructive symptoms. CONCLUSIONS Fibrous thyroiditis should be considered in the differential diagnosis of primary hypothyroidism in a patient with a stony-hard goiter. Although steroids are often used as a therapeutic strategy for this disease, our patient had an excellent therapeutic response to tamoxifen, avoiding adverse effects associated with steroid therapy, the higher cost of monoclonal antibody therapy, and surgery-associated risks.
Riedel 甲状腺炎是一种罕见的 IgG4 相关的甲状腺弥漫性纤维性炎症;由于其发病率低,目前尚无标准化的治疗指南。虽然并发症并不常见,但坚硬如石的甲状腺肿引起的阻塞症状可能会危及患者的生命。诊断必须通过活检证实,治疗包括甲状腺激素替代和抗炎药物,尽管有时可能需要甲状腺切除术。
一名 69 岁女性因进行性甲状腺功能减退和阻塞性吞咽困难就诊,病史为 7 个月。体格检查发现甲状腺肿大,质地坚硬。多普勒超声检查显示甲状腺肿大,呈巨大、无血管性。计算机断层扫描未能显示异常组织的甲状腺外扩展。对甲状腺进行 Tru-Cut 活检。观察到明显的纤维组织带广泛替代甲状腺滤泡,滤泡闭塞和轻度局灶性闭塞性静脉炎。明确识别出淋巴浆细胞浸润;未发现嗜酸性细胞或巨细胞。免疫组织化学检查显示浆细胞浸润的 IgG4/IgG 比值为 40%;还发现血清 IgG4 水平升高,支持 Riedel 甲状腺炎的诊断。该患者成功接受左甲状腺素替代和他莫昔芬治疗,阻塞症状迅速缓解。
在坚硬如石的甲状腺肿患者中,应考虑将纤维性甲状腺炎作为原发性甲状腺功能减退的鉴别诊断。尽管类固醇常被用作该疾病的治疗策略,但我们的患者对他莫昔芬有极好的治疗反应,避免了类固醇治疗相关的不良反应、单克隆抗体治疗的更高成本以及手术相关的风险。